CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
P/B ratio for CureVac N.V. (CVAC)
P/B ratio as of 2023: 1.63
According to CureVac N.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.63. At the end of 2022 the company had a P/B ratio of 2.00.
P/B ratio history for CureVac N.V. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.63 |
| 2022 | 2.00 |
| 2021 | 8.15 |
| 2020 | 12.33 |
| 2019 | -217.67 |
| 2018 | 267.35 |